AUG 22, 2018 9:43 PM PDT

New Clinical Assay Useful For Urothelial Cancer

WRITTEN BY: Nouran Amin

U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in urothelial carcinoma. The assay is the only approved companion diagnostic to help identify patients with urothelial carcinoma for treatment with KEYTRUDA, which is a monoclonal anti-PD1 therapy manufactured by the pharmaceutical company known Merck for the first-line treatment option of cancer.

Specifically, KEYTRUDA is approved for cancer patients experiencing locally advanced or metastatic urothelial carcinoma and who are not eligible for cisplatin-containing chemotherapy. Additionally, their tumors must express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined through an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy.

The pharmDx assay referred to as ‘PD-L1 IHC 22C3’ follows previous FDA-approved assay for non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and cervical cancer. "Anti-PD-1 therapies are a promising treatment class for many cancer types, and early PD-L1 testing can provide critical information to physicians managing urothelial carcinoma patients," explains Sam Raha, the president of Agilent's Diagnostics and Genomics Group. "By expanding the use of PD-L1 IHC 22C3 pharmDx, Agilent strives to address the unmet need for treatment options in patients who are ineligible for cisplatin-containing chemotherapy. Through these efforts, we maintain our commitment to bringing companion diagnostics to the market in support of groundbreaking immuno-oncology therapeutics."

The 5th most common cancer in the United States, urothelial carcinoma holds an estimated incidence of 81,000 new diagnoses in just 2018. For 30 years, cancer-related morality has not approved for patients with advanced/metastatic urothelial carcinoma with a five-year survival rate of approximately 15%. Additionally, the age along with disease-associated comorbidities affect patient eligibility for standard treatments such as cisplatin-containing chemotherapy. Patients that cannot be administered cisplatin-containing chemotherapy, will have an unmet need for effective therapy.

Source: Agilent

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 02, 2019
Clinical & Molecular DX
SEP 02, 2019
A Blood Drop Test for Rapid Detection of Traumatic Brain Injury
A study published by Yue et al., in August 2019, reported that a simple blood test (a few drops of blood) can detect traumatic brain injury efficiently and...
OCT 07, 2019
Clinical & Molecular DX
OCT 07, 2019
The Three Common Herbs Combating High Blood Pressure: Molecular Mechanism Revealed
Hypertension is also known as high blood pressure is a serious condition. According to the Centers for Disease Control and Prevention, about 1 of...
OCT 09, 2019
Neuroscience
OCT 09, 2019
Elderly Depression Remains Consistant As Antidepressant Use Doubles
  A new study from the University of East Anglia finds that despite a 2-fold increase in antidepressant use, depression among individuals 65 and older...
NOV 07, 2019
Neuroscience
NOV 07, 2019
Reading, Hearing Language Connects Meaning to Same Region in the Brain
Scientists at the University of California Berkeley used improved functional MRI resolution to show that similar neural circuits in the same regions of the...
DEC 05, 2019
Clinical & Molecular DX
DEC 05, 2019
Catching drug-resistant HIV mutants with next generation sequencing
Human immunodeficiency virus (HIV)-positive individuals are treated with antiretroviral therapies to reduce the amount of circulating virus, restore their...
FEB 10, 2020
Microbiology
FEB 10, 2020
As Ebola Outbreak Continues, Researchers Create Faster Genetic Test
Since 2013, around 30,000 people have been infected during several outbreaks of Ebola in eight different countries....
Loading Comments...